While chronic alterations in cardiac triacylglycerol (TAG) metabolism and accumulation are associated with cardiomyopathy, it is unclear whether TAG catabolizing enzymes such as adipose triglyceride lipase (ATGL) play a role in acquired cardiomyopathies. Importantly, germline deletion of ATGL leads to marked cardiac steatosis and heart failure in part through reducing peroxisome proliferator-activated receptor a (PPARa) activity and subsequent fatty acid oxidation (FAO). However, whether ATGL deficiency specifically in adult cardiomyocytes contributes to impaired PPARa activity, cardiac function, and metabolism is not known.
Introduction
Under physiological conditions, the heart relies primarily on mitochondrial fatty acid (FA) oxidation (FAO) for ATP production. 1 Upon entry into the cardiomyocyte, FAs that are not immediately oxidized are esterified to triacylglycerol (TAG) and stored in cytosolic lipid droplets. 2 However, chronically increased myocardial TAG content (i.e. myocardial steatosis) observed in certain diseases is associated with cardiomyopathy in both rodents and humans. 3 -9 Having said that, it is unlikely that intramyocardial TAGs per se directly cause cardiomyocyte dysfunction. 10 -15 Instead, it is more probable that changes in TAG metabolism indirectly contribute to cardiac dysfunction by influencing myocardial † These authors contributed equally. ‡ Present address: Dalhousie Medicine New Brunswick, Department of Biochemistry and Molecular Biology, Dalhousie University, E2L 4L5 Saint John, New Brunswick, Canada. accumulation of lipotoxic FA metabolites, such as ceramides, diacylglycerols, long-chain acyl-CoAs, or acylcarnitines. Previous work has identified adipose triglyceride lipase (ATGL) as rate limiting for cytosolic TAG hydrolysis in many tissues. 16 The importance of ATGL action in the heart is supported by the observation that patients with mutations in the ATGL gene (PNPLA2) exhibit myocardial steatosis and cardiomyopathy. 17 -21 Increased myocardial TAG accumulation is associated with cardiomyopathy in humans during conditions such as obesity, insulin resistance, diabetes mellitus, and ageing, 3,9,22 -27 suggesting that alterations in myocardial TAG metabolism and specifically ATGL may also play a role in acquired human cardiomyopathies.
Similar to humans with (inactivating) ATGL mutations, mice with constitutive whole body ATGL deficiency (totalAtglKO) showed markedly increased myocardial TAG accumulation, which was associated with reduced peroxisome proliferator-activated receptor a (PPARa) activity, leading to mitochondrial dysfunction and lethal cardiomyopathy. 28 These data suggest that myocardial ATGL is crucial for PPARa activation and mitochondrial function. 28 In addition to these metabolic derangements, totalAtglKO mice also presented with cardiac fibrosis and increased ventricular wall dimensions. 16, 28 However, since whole body ATGL deficiency results in potentially confounding effects such as reduced serum lipid levels, altered concentrations of circulating adipokines, and impaired insulin secretion, 16, 29 as well as developmental adaptations due to germline ATGL deficiency, it is not clear whether acquired cardiac ATGL deficiency in the adult cardiomyocyte would recapitulate the cardiac metabolic phenotype observed in the totalAtglKO mice. In addition, it is unknown whether cardiac fibrosis in totalAtglKO mice was a direct effect of ATGL deficiency in cardiac fibroblasts.
The aim of this study was to determine whether short term, acquired ATGL deficiency in adult cardiomyocytes contributes to impaired cardiac function, metabolism, and remodelling.
Methods
An expanded Methods section is available in the Supplementary material online.
Generation of the Atgl/Pnpla2-loxP targeting construct and icAtglKO mice
Mice carrying a LoxP-modified Atgl allele (B6.129-Pnpla2 tm1Eek mice; herein designated as Atgl-flox mice) were generated in the laboratory of Erin Kershaw using BAC recombineering. Atgl-flox mice [backcrossed onto the C57BL/6NTac (Taconic) background for more than four generations] were interbred with B6.Cg-Tg(Myh6-cre/Esr1)1Jmk/J mice (#005657, The Jackson Laboratory, backcrossed onto the C57BL/6J background for .10 generations), which express a tamoxifen-inducible Cre recombinase driven by the cardiomyocyte-specific a-myosin heavy chain promoter (offspring are estimated to have .96.9% C57BL/6 background). The C57BL/6J, but not C57BL/6NTac subline harbours a mutation in the gene encoding nicotinamide nucleotide transhydrogenase, which promotes antioxidant capacity in mitochondria and is expressed in the heart. 30 Control and icAtglKO mice were derived from the same breeder pairs to avoid confounding effects due to differences in genetic background. Tamoxifen (#T5648, Sigma) dissolved in corn oil was administered orally to adult control (homozygous Atgl-flox without Cre, Atgl flox/flox 2/2) and inducible cardiomyocyte-specific ATGL knockout (icAtglKO; homozygous Atgl-flox and hemizygous for Cre, Atgl flox/flox Cre/2) mice at a dose of 80 mg/kg/ day for six consecutive days. Mice were housed on a 12 h light:12 h dark cycle with ad libitum access to chow diet (#5001 from Lab Diet with 13.5% kcal from fat) and water. Unless otherwise stated, non-fasted mice were used and euthanasia was performed by decapitation. All protocols involving mice were approved by the University of Alberta Institutional Animal Care and Use Committee and conform with the Guide for the Care and Use of Laboratory Animals published by the United States National Institutes of Health.
Analysis of serum insulin, lipids, and lactate
Serum insulin was determined using the mouse insulin enzyme-linked immunosorbent assay kit (#90080, Crystal Chem). Serum free fatty acids (FFA) and TAGs were determined using colorimetric kit assays [#HR Series NEFA-HR(2), Wako and #2780 -400H Infinity TAG reagent, Thermo Electron]. Serum lactate was determined using a fluorometric kit assay (#700510, Cayman).
Echocardiography
Mice were mildly anaesthetized using 0.75% isoflurane, and transthoracic echocardiography was performed as described previously. 31 
Heart perfusions
Hearts were perfused aerobically in working mode with Krebs -Henseleit buffer containing 0.8 mmol/L oleate prebound to 3% delipidated bovine serum albumin, 5 mmol/L glucose, and 50 mU/mL insulin for 60 min as described previously. 31 
Cardiomyocyte isolation
Ventricular calcium-tolerant myocytes were isolated from Langendorff perfused hearts similar to a previously described procedure. 32 
Tissue homogenization and lipid analysis
Tissues were homogenized as described previously. 31 Lipids were isolated from homogenates, followed by the colorimetric determination of TAG concentrations. To examine oleate incorporation into TAGs from perfused hearts, TAGs were isolated by thin layer chromatography, and labelled oleate was measured by liquid scintillation counting.
Immunoblot analysis
Tissue lysates were resolved by SDS -PAGE and immunoblot analysis was performed as described previously. 31 
Mitochondrial enzyme activities and ATP production
Citrate synthase and b-hydroxyacyl-CoA dehydrogenase (HADH) activity in ventricular homogenates was assessed spectrophotometrically according to Boudina et al. 33 with modifications. ATP synthesis rates in freshly isolated mitochondria were measured using a bioluminescence-based method employing firefly luciferase. 34 
Gene expression
Gene expression analysis was performed by quantitative reverse transcriptase PCR as previously described 35 (see Supplementary material online, Table S1 ).
Microarray analysis
Total RNA was isolated from frozen ventricular tissue using TRIzol reagent (Invitrogen), and microarray analysis was performed as described previously 36 with modifications. Differentially expressed genes were identified using the moderated t-test with the R/Bioconductor package limma. Multiple hypothesis testing was considered according to the method of Benjamini and Hochberg. 37 
Histology
Haematoxylin and eosin (H&E) and Masson's trichrome (M.T.) stains of paraffin-embedded sections were visualized as described previously. 31 
Electron microscopy and mitochondrial morphometry
Electron microscopy was performed as previously described. 38 Intermyofibrillar mitochondria, which were entirely included in the field of view, were quantified from images at 7100-fold magnification. Mitochondrial crosssectional area and minimum and maximum Feret's diameter were determined using ImageJ software (National Institutes of Health).
Statistical analysis
Results are expressed as means + SEM. Comparisons between groups were made by the unpaired two-tailed Student t test using the GraphPad Prism software, unless otherwise stated. P-values of ,0.05 were considered statistically significant.
Results

Inducible cardiomyocyte-specific ATGL deficiency results in myocardial steatosis and fibrotic remodelling
ATGL protein expression was diminished in ventricles and isolated cardiomyocytes from icAtglKO mice compared with control mice ( Figure 1A) , confirming ablation of ATGL protein. Cardiomyocytes isolated from icAtglKO mice also exhibited a drastically altered morphology with large vacuoles ( Figure 1B) . Similar to previous observations in totalAtglKO and striated muscle-specific ATGL knockout (muscleAtglKO) mice, 28 the cardiac TAG content was markedly increased in icAtglKO mice (Figures 1C, D and 5D). Serum concentrations of FFA, TAGs, insulin, and lactate were unchanged between genotypes ( Figure 1E -H ). These findings show that ATGL specifically in cardiomyocytes is rate limiting for myocardial TAG catabolism.
Histological analysis showed significantly altered tissue morphology in hearts from icAtglKO mice, which was characterized by accumulation of vacuoles as well as interstitial fibrosis ( Figure 1I ) (15.53 + 0.51% fibrosis area in icAtglKO compared with none in control hearts, averages of two to three images per heart×3 hearts per group). Fibrotic remodelling in hearts from icAtglKO mice also corresponded with increased collagen (Col1a1) and transforming growth factor b (Tgfb) mRNA expression ( Figure 1J ). In addition, microarray analysis showed up-regulation of numerous genes involved in extracellular matrix remodelling in hearts from icAtglKO mice, including periostin (Postn), kallikrein-related peptidase 7 (Klk7), collagen type I (Col1a1 and Col1a2) and III (Col3a1), reticulon 4 (Nogo, Rtn4), CD44 antigen (CD44), chemokine (C-C motif) receptor 2/5 (Ccr2/Ccr5), decorin (Dcn), and galectin-3 (Lgals3) ( Figure 2A ). Together, these findings suggest that icAtglKO mice develop rapid fibrotic myocardial remodelling in parallel with cardiac steatosis.
Protein expression of the apoptosis markers, phospho-P38 mitogenactivated protein kinase (MAPK) (Thr180/Tyr182), and phospho-c-Junamino-terminal kinase (JNK) (Thr183/Tyr185) was comparable between hearts from icAtglKO and control mice ( Figure 2B and C) , although expression of cleaved Poly(ADP-Ribose) Polymerase (PARP) trended to increase in hearts from icAtglKO mice ( Figure 2D) . These data indicate the absence of marked induction of apoptosis following short-term ATGL ablation and are consistent with low levels of apoptosis in hearts from totalAtglKO mice. 16 3.2 Inducible cardiomyocyte-specific ATGL deficiency leads to moderate in vivo cardiac dysfunction Examination of in vivo cardiac function using transthoracic echocardiography revealed that ejection fraction and fractional shortening were reduced by 15 and 18%, respectively, in hearts from icAtglKO mice ( Figure 3A-C ) , which also corresponded with reduced peak systolic mitral annular velocity (S ′ ) ( Table 1) . Despite unchanged diastolic parameters such as the ratio of early (E) to late (A) transmitral filling velocity ( Figure 3D) , mitral valve deceleration time ( Figure 3E) , and isovolumic relaxation time ( Figure 3F ), early and late diastolic mitral annular velocity (E ′ and A ′ , respectively) ( Figure 3G , Table 1 ) were decreased in hearts from icAtglKO mice with concomitantly increased ratio of E to E ′ ( Figure 3H) , indicating elevated left ventricular filling pressure in icAtglKO mice. Together, these data suggest that icAtglKO mice exhibit modest cardiac dysfunction in vivo.
Inducible cardiomyocyte-specific ATGL deficiency leads to hypertrophy
Since hearts from icAtglKO mice are so lipid laden, we tested whether true hypertrophic remodelling contributes to the enlarged appearance of cardiomyocytes and hearts from icAtglKO mice ( Figure 1B and C ). The ventricle weight-to-tibia length ratio ( Figure 4A ) and the left ventricular mass as assessed by echocardiography ( Table 1) were significantly increased in icAtglKO mice compared with controls. Histological images of long-axis heart sections also showed increased ventricle wall thickness in icAtglKO mice ( Figure 4B ). Assessment of ventricular wall dimensions and left ventricular internal diameters in diastole and systole (LVIDd and LVIDs, respectively) using echocardiography confirmed increased thickness of the interventricular septum and left ventricular posterior wall in icAtglKO mice in the absence of ventricular dilatation ( Figure 4C and D, Table 1 ). Most importantly, transcript levels of brain natriuretic peptide (Nppb) and beta myosin heavy chain (Myh7), which are marker genes for pathological hypertrophy, were correspondingly up-regulated in hearts from icAtglKO mice ( Figure 4E ). In accordance with this finding, microarray analysis showed up-regulation of several genes involved in pathological hypertrophic growth, such as signal transducer and activator of transcription 5A (Stat5a), follistatin-like 1 (Fstl1), and b-catenin (Ctnnb1) (Figure 2A ). In addition, phosphorylation and protein expression of STAT3, which is also an indicator of cardiac hypertrophy, was increased in hearts from icAtglKO mice ( Figure 4F) . In contrast, protein expression of catalase ( Figure 4G) , manganese superoxide dismutase (MnSOD) ( Figure 4H) , and 4-hydroxy-2-nonenal (4-HNE) Michael adducts ( Figure 4I ; n ¼ 5-6, P ¼ 0.96) was not increased in hearts from icAtglKO mice, suggesting that hypertrophic and fibrotic remodelling of the myocardium is not due to increased oxidative stress in icAtglKO mice. Taken together, these findings suggest that icAtglKO mice develop overt hypertrophic remodelling in the absence of increased oxidative stress.
Inducible cardiomyocyte-specific ATGL deficiency results in diminished myocardial FAO
We determined FA and glucose oxidation rates in ex vivo perfused working hearts using radiolabelled substrates. Ex vivo cardiac power was comparable between genotypes (see Supplementary material online, Figure S2A ), but was reduced in hearts from icAtglKO mice when normalized to cardiac dry weight ( Figure 5A ). Oleate oxidation rates were decreased in hearts from icAtglKO mice compared with controls ( Figure 5B , see Supplementary material online, Figure S2B ), which was not associated with a compensatory increase in glucose oxidation rates ( Figure 5C , see Supplementary material online, Figure S2C ). Incorporation of oleate into the TAG pool was decreased in hearts from icAtglKO mice ( Figure 5E ), suggesting that enhanced sequestration of labelled oleate in TAGs does not confound oleate oxidation rates measured in these hearts. Interestingly, reduced FAO and FA incorporation into TAGs were also associated with decreased protein expression of the FA translocase, CD36, but not FATP1 ( Figure 5G ). In addition, the activity of the FAO enzyme, HADH, was also decreased in hearts from icAtglKO mice ( Figure 5F ). Together, these data suggest that reduced myocardial FAO likely contributes to the cardiac contractile dysfunction in vivo in icAtglKO mice.
Inducible cardiomyocyte-specific ATGL deficiency does not dramatically impair PPARa activity
Contrary to our expectations, we found that PPARa protein expression was increased in hearts from icAtglKO mice ( Figure 5H) and that mRNA expression of PPARa (Ppara) and the PPARa target genes, 1acylglycerol-3-phosphate O-acyltransferase 3 (Agpat3), pyruvate dehydrogenase kinase isozyme 4 (Pdk4), medium-chain acyl-CoA dehydrogenase (Mcad), and mitochondrial acyl-CoA thioesterase 1 (Mte1) was unimpaired in hearts from non-fasted icAtglKO mice ( Figure 5I ). In addition, mRNA expression of diacylglycerol O-acyltransferase 2 (Dgat2) and glucose transporter type 1 (Glut1) was also unchanged in hearts from icAtglKO mice ( Figure 5I ).Microarray analysis likewise showed no significant changes in the expression of PPARa, PPARa target genes, and other genes involved in FA utilization (data not shown). However, a relatively moderate reduction in the mRNA expression of some PPARa target genes was observed in hearts from icAtglKO mice following prolonged (12 h) fasting ( Figure 5J) . These findings suggest that PPARa target gene expression is not significantly impaired in hearts from icAtglKO mice in the non-fasted and short-term fasted state, but may become more physiologically relevant during prolonged fasting. Interestingly, hormone-sensitive lipase (HSL) phosphorylation at Ser660 was increased in hearts from icAtglKO mice ( Figure 5K) , suggestive of enhanced HSL activation that may contribute to sustained PPARa target gene expression.
To determine the impact of inducible cardiomyocyte-specific ATGL deficiency on mitochondria directly, we assessed multiple mitochondrial parameters. Inspection of myocardial tissue morphology by transmission electron microscopy revealed dramatically enlarged lipid droplets in the intermyofibrillar space in proximity to mitochondria ( Figure 6A) . However, no clear differences were noted between genotypes for mitochondria shape or ultrastructural characteristics ( Figure 6A) . More objective quantification of mitochondrial number ( Figure 6B) as well as individual mitochondrial area ( Figure 6D ) and diameter ( Figure 6E and F ) revealed that these parameters did not differ between genotypes. In addition, citrate synthase activity ( Figure 6C) , a surrogate measure of both mitochondrial mass and Krebs cycle activity, was similar between genotypes. ATP production rates via complex I (pyruvate/malate) were not significantly different between genotypes, but were reduced via complex II (succinate/rotenone) and IV (TMPD/ascorbate) as well as in the absence of exogenous substrate (ADP only) in icAtglKO mitochondria ( Figure 6G) . Together, these data suggest that inducible cardiomyocyte-specific ATGL deficiency does not significantly impact mitochondrial morphology or mass, but impairs mitochondrial function at the level of ATP synthesis. Moreover, hearts from icAtglKO mice displayed areas of myofibrillar disarray ( Figure 6A) , which may contribute to hypertrophic remodelling.
Lastly, to examine whether increased accumulation of lipotoxic FA metabolites could underlie mitochondrial dysfunction in hearts from icAtglKO mice, we measured the cardiac content of ceramides and longchain acyl-CoAs ( Figure 6H and I ) . Interestingly, cardiac levels of ceramides and long-chain acyl-CoA species were unchanged or decreased in hearts from icAtglKO mice, suggesting that mitochondrial dysfunction in these hearts was not secondary to increased accumulation of these lipotoxic FA metabolites.
Discussion
In this study, we tested whether acquired impairment of myocardial TAG catabolism via induced cardiomyocyte-specific ATGL deficiency influences mitochondrial substrate metabolism as well as cardiac structure and function and investigated whether this was associated with impaired PPARa signalling.
As expected, hearts from icAtglKO mice exhibited a substantial increase in myocardial TAG content that is comparable with that observed in constitutive totalAtglKO and muscleAtglKO mice. 28 In addition, hearts from icAtglKO mice exhibited extensive interstitial fibrosis that was caused by the up-regulation of several genes related to extracellular matrix remodelling. Although increased fibrosis was also observed in hearts from totalAtglKO mice, 16 it was unclear whether these effects were a result of ATGL deficiency in cardiomyocytes or other cardiac cell types, such as collagen-producing fibroblasts. Our findings suggest that fibrotic remodelling following ATGL ablation is the result of intercellular signalling from cardiomyocytes to fibroblasts and ensuing up-regulation of profibrotic genes. Since fibrosis can cause increased systolic and diastolic stiffness, our data support the conclusion that increased fibrotic remodelling contributes to cardiac dysfunction in icAtglKO mice. Interestingly, hearts from icAtglKO mice also develop overt pathological hypertrophy. Although the precise mechanisms of hypertrophic remodelling in hearts from icAtglKO mice require further investigation, it is possible that excessive TAG deposition in cardiomyocytes leads to intracellular mechanical stretch that perturbs the myofibrillar organization, thereby triggering a pro-hypertrophic response to compensate for these adverse changes in myofibril arrangement and function. This notion is supported by the finding that myofibrillar disarray and dysfunction secondary to mutations in sarcomeric proteins are causative for the development of compensatory hypertrophic remodelling in familial hypertrophic cardiomyopathy. 39 Similar to findings using crude cardiac homogenates from totalAtglKO mice, 28 FAO was reduced in working hearts from icAtglKO mice, which was not compensated by increased glucose oxidation. However, it is possible that the rate of glucose oxidation via TCA cycle anaplerosis is augmented in hearts from icAtglKO mice, which could not be detected using the perfusion system employed in this study. Indeed, previous studies have demonstrated that hypertrophied hearts exhibit decreased FAO, unchanged glucose oxidation, but increased diversion of glucosederived pyruvate towards anaplerosis. 40 Interestingly, mRNA expression of PPARa target genes was maintained in hearts from icAtglKO mice in the non-fasted and short-term (5 h) fasted state and only mildly reduced with prolonged (12 h) fasting. Possible reasons for this milder effect on myocardial PPARa signalling in icAtglKO mice include differences in background strain (.96.9% C57BL/6 for icAtglKO vs. pure, .99.91% C57BL/6 for tota-lAtglKO mice, and 93.8-96.9% C57BL/6 for muscleAtglKO mice), the duration of ATGL deficiency (4-6 weeks in icAtglKO vs. at least 8 weeks and 15-16 weeks, not including time in utero, in totalAtglKO mice and muscleAtglKO mice, respectively), and the age at the onset of ATGL deficiency (ablation in adult icAtglKO mice vs. congenital deficiency in totalAtglKO and muscleAtglKO mice). Although we cannot exclude the possibility that sufficient residual ATGL activity is still present in hearts from icAtglKO mice to maintain PPARa signalling at baseline, this is not sufficient to prevent marked cardiac steatosis. However, it is conceivable that up-regulation of HSL activity via increased phosphorylation at Ser660 could partially rescue the effect of ATGL ablation on cardiac TAG accumulation and PPARa signalling. It should be noted that cardiac-specific HSL over-expression protected from fasting-and diabetes-induced cardiac steatosis, 41, 42 indicating that up-regulation of HSL in hearts from icAtglKO mice could compensate to some extent for the lack of ATGL. Interestingly, Reilich et al. 19 also suggested that b-adrenergic agonist-mediated HSL activation in cells from patients with inactivating ATGL/PNPLA2 mutations was able to bypass the lipolytic blockade.
PPARa agonist treatment of totalAtglKO mice protected from cardiac steatosis, mitochondrial dysfunction, and heart failure. 28 Nonetheless, a beneficial effect of PPARa agonist treatment on cardiac function in humans with ATGL/PNPLA2 mutations has yet to be demonstrated. 20 Although we have not tested this in the present study, it is likely that over-activation of PPARa via PPARa agonist treatment improves cardiac steatosis and function in icAtglKO mice by increasing oxidation of FAs taken up into cardiomyocytes in the absence of enhanced TAG catabolism, as has been previously demonstrated using totalAtglKO mice. 28 Regardless of the differences in PPARa signalling between mouse models, the findings of this study suggest that mechanisms other than changes in PPARa signalling also contribute to impaired FAO in hearts from icAtglKO mice. Consistent with the concept that a significant proportion of FAs in the heart are shuttled through the TAG pool prior to being oxidized in the mitochondria, 1, 43 it is likely that a decrease in FAs liberated by TAG hydrolysis may contribute to the reduction in myocardial FAO in icAtglKO mice. In addition, CD36 protein expression and FA incorporation into the TAG and FFA pool (data not shown) were decreased in hearts from icAtglKO mice, suggesting that decreased cardiomyocyte FA uptake via CD36 may also contribute to diminished FAO in the absence of marked changes in PPARa signalling.
In summary, acquired cardiomyocyte-specific ATGL deficiency leads to marked myocardial steatosis, pathological hypertrophy, as well as fibrotic remodelling, which are associated with moderate cardiac dysfunction in vivo. Furthermore, mitochondrial FAO is impaired in hearts from icAtglKO mice, even in the absence of marked changes in cardiac PPARa signalling.
